Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC theta inhibitors.
Katoh, T., Takai, T., Yukawa, T., Tsukamoto, T., Watanabe, E., Mototani, H., Arita, T., Hayashi, H., Nakagawa, H., Klein, M.G., Zou, H., Sang, B.C., Snell, G., Nakada, Y.(2016) Bioorg Med Chem 24: 2466-2475
- PubMed: 27117263 
- DOI: 10.1016/j.bmc.2016.04.008
- Primary Citation of Related Structures:  
5F9E - PubMed Abstract: 
A high-throughput screening campaign helped us to identify an initial lead compound (1) as a protein kinase C-θ (PKCθ) inhibitor. Using the docking model of compound 1 bound to PKCθ as a model, structure-based drug design was employed and two regions ...